Who owns ENTRADA THERAPEUTICS INC?
- Ticker: TRDA
- CUSIP Number: 29384c108
Tip: Access positions for across all investors
Analyze quarterly positions in Entrada Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Entrada Therapeutics stock
Who bought or sold ENTRADA THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Baker Bros. Advisors | 4.9M | $69M | 0% | Mar 2024 |
|
MPM Asset Management | 4.4M | $63M | 0% | Mar 2024 |
|
5AM Venture Management | 4.4M | $63M | 0% | Mar 2024 |
|
T. Rowe Price Associates | 2.8M | $39M | -9% | Mar 2024 |
|
BlackRock | 1.5M | $21M | 6% | Mar 2024 |
|
Redmile Group | 1.3M | $18M | 0% | Mar 2024 |
|
Vanguard Group | 1.1M | $15M | 1% | Mar 2024 |
|
Wellington Management Company | 1.0M | $16M | 0% | Dec 2023 |
|
StepStone | 761k | $11M | 0% | Mar 2024 |
|
Geode Capital Management | 475k | $6.7M | 8% | Mar 2024 |
|
American Century Companies | 366k | $5.2M | 164% | Mar 2024 |
|
Northern Trust | 199k | $2.8M | -3% | Mar 2024 |
|
FMR | 168k | $2.4M | -71% | Mar 2024 |
|
Charles Schwab Investment Management | 157k | $2.2M | 3% | Mar 2024 |
|
Bank of New York Mellon | 111k | $1.6M | -4% | Mar 2024 |
|
Morgan Stanley | 108k | $1.5M | 414% | Mar 2024 |
|
Moore Capital Management | 105k | $1.5M | 0% | Mar 2024 |
|
Advantage Alpha Capital Partners | 91k | $1.3M | 100% | Mar 2024 |
|
Millennium Management | 72k | $1.0M | 200% | Mar 2024 |
|
TD Asset Management | 71k | $1.0M | -40% | Mar 2024 |
|
Citadel Advisors | 70k | $987k | 100% | Mar 2024 |
|
Nuveen Asset Management | 57k | $810k | -22% | Mar 2024 |
|
Citigroup | 56k | $788k | 1710% | Mar 2024 |
|
Marshall Wace | 52k | $733k | 100% | Mar 2024 |
|
Corton Capital | 41k | $583k | 44% | Mar 2024 |
|
Squarepoint Ops | 34k | $483k | 100% | Mar 2024 |
|
Winton Capital | 33k | $461k | 100% | Mar 2024 |
|
Natixis | 31k | $433k | 0% | Mar 2024 |
|
Connor, Clark & Lunn Investment Management | 31k | $436k | 100% | Mar 2024 |
|
Rhumbline Advisers | 30k | $418k | 3% | Mar 2024 |
|
Schonfeld Strategic Advisors | 29k | $410k | 100% | Mar 2024 |
|
New York Life Investment Management | 26k | $367k | 100% | Mar 2024 |
|
OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 26k | $364k | 7% | Mar 2024 |
|
UBS Group | 24k | $333k | 4% | Mar 2024 |
|
Swiss National Bank | 23k | $326k | 0% | Mar 2024 |
|
Bank of America Corporation | 23k | $320k | -18% | Mar 2024 |
|
Barclays | 23k | $318k | -29% | Mar 2024 |
|
Oracle Alpha | 17k | $246k | 39% | Mar 2024 |
|
Goldman Sachs Group | 17k | $246k | -4% | Mar 2024 |
|
Man Group | 17k | $238k | 100% | Mar 2024 |
|
Credit Suisse | 16k | $228k | 1% | Mar 2024 |
|
Allspring Global Investments Holdings | 15k | $209k | 428% | Mar 2024 |
|
Harbor Capital Advisors | 15k | $206k | 100% | Mar 2024 |
|
Franklin Resources | 14k | $203k | 8% | Mar 2024 |
|
Arrowstreet Capital, Limited Partnership | 14k | $203k | 100% | Mar 2024 |
|
CornerCap Investment Counsel | 13k | $186k | 100% | Mar 2024 |
|
California State Teachers Retirement System | 13k | $179k | -16% | Mar 2024 |
|
PDT Partners | 13k | $178k | 100% | Mar 2024 |
|
MetLife Investment Advisors | 12k | $177k | 0% | Dec 2023 |
|
Legal & General Group | 11k | $157k | 0% | Mar 2024 |
|
American International | 11k | $161k | 0% | Dec 2023 |
|
Deutsche Bank Aktiengesellschaft | 10k | $143k | 3% | Mar 2024 |
|
New York State Common Retirement Fund | 8.9k | $126k | 0% | Mar 2024 |
|
Jpmorgan Chase & Co | 8.4k | $119k | -41% | Mar 2024 |
|
SG Americas Securities | 7.7k | $109k | -34% | Mar 2024 |
|
Wells Fargo & Company | 7.6k | $108k | 15% | Mar 2024 |
|
Acadian Asset Management | 5.7k | $79k | 100% | Mar 2024 |
|
Lazard Asset Management | 2.7k | $40k | 100% | Dec 2023 |
|
New York State Teachers Retirement System | 1.9k | $27k | 100% | Mar 2024 |
|
Summit Investment Advisors | 1.8k | $25k | 0% | Mar 2024 |
|
Metropolitan Life Insurance Company | 1.2k | $18k | 0% | Dec 2023 |
|
Royal Bank of Canada | 1.1k | $16k | -84% | Mar 2024 |
|
Plato Investment Management | 1.1k | $16k | 100% | Mar 2024 |
|
Federated Investors | 908.00 | $14k | 100% | Dec 2023 |
|
Amalgamated Bank | 721.00 | $10k | -61% | Mar 2024 |
|
Tower Research Capital | 435.00 | $6.2k | -57% | Mar 2024 |
|
GAMMA Investing | 40.00 | $567.000000 | 100% | Mar 2024 |
|
NISA Investment Advisors | 31.00 | $439.000300 | 210% | Mar 2024 |
|
Russell Investments | 9.00 | $127.999800 | 0% | Mar 2024 |
|
Nelson, Van Denburg & Campbell Wealth Management | 4.00 | $56.000000 | 100% | Mar 2024 |
|
CWM | 1.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Entrada Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
72 Investment Holdings | Dec 2023 | 173k | $2.6M |
Mirae Asset Global Investments | Dec 2023 | 11k | $164k |
State of Wyoming | Dec 2023 | 5.9k | $90k |